D. E. Shaw & Co. Inc. Raises Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

D. E. Shaw & Co. Inc. lifted its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 47.5% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 845,560 shares of the biopharmaceutical company’s stock after purchasing an additional 272,389 shares during the quarter. D. E. Shaw & Co. Inc. owned about 1.28% of Celldex Therapeutics worth $31,294,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of CLDX. Price T Rowe Associates Inc. MD raised its holdings in shares of Celldex Therapeutics by 631.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,087,208 shares of the biopharmaceutical company’s stock worth $129,571,000 after buying an additional 2,664,915 shares during the last quarter. Point72 Asset Management L.P. lifted its position in Celldex Therapeutics by 105.3% during the 4th quarter. Point72 Asset Management L.P. now owns 2,756,122 shares of the biopharmaceutical company’s stock worth $109,308,000 after acquiring an additional 1,413,722 shares during the period. Wellington Management Group LLP grew its stake in Celldex Therapeutics by 19.2% during the 4th quarter. Wellington Management Group LLP now owns 6,476,561 shares of the biopharmaceutical company’s stock valued at $256,860,000 after purchasing an additional 1,044,728 shares during the last quarter. Jennison Associates LLC increased its holdings in shares of Celldex Therapeutics by 3,327.0% in the first quarter. Jennison Associates LLC now owns 688,080 shares of the biopharmaceutical company’s stock valued at $28,879,000 after purchasing an additional 668,002 shares during the period. Finally, Vanguard Group Inc. raised its stake in shares of Celldex Therapeutics by 19.8% in the first quarter. Vanguard Group Inc. now owns 3,650,582 shares of the biopharmaceutical company’s stock worth $153,215,000 after purchasing an additional 604,251 shares during the last quarter.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Wells Fargo & Company upgraded Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Thursday. Stifel Nicolaus started coverage on shares of Celldex Therapeutics in a report on Tuesday, June 18th. They issued a “buy” rating and a $58.00 price objective on the stock. Wolfe Research cut shares of Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a report on Friday. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 price target on shares of Celldex Therapeutics in a report on Thursday. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $67.00 price objective on shares of Celldex Therapeutics in a research note on Monday, September 16th. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Celldex Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $63.83.

Celldex Therapeutics Stock Performance

CLDX stock opened at $33.20 on Friday. Celldex Therapeutics, Inc. has a one year low of $22.11 and a one year high of $53.18. The firm’s fifty day moving average is $38.35 and its 200 day moving average is $38.34. The firm has a market cap of $2.19 billion, a PE ratio of -11.65 and a beta of 1.56.

Celldex Therapeutics (NASDAQ:CLDX) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.54) EPS for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.05. Celldex Therapeutics had a negative return on equity of 23.66% and a negative net margin of 1,809.18%. The firm had revenue of $2.50 million for the quarter, compared to analysts’ expectations of $1.13 million. Research analysts predict that Celldex Therapeutics, Inc. will post -2.5 earnings per share for the current fiscal year.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.